A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients

Covid-19 infection in kidney transplant recipients: a case report

Superior outcomes in HIV-positive kidney transplant patients compared to HCV-infected or HIV/HCV co-infected recipients

The prerequisite for an 'undetectable' HIV viral load has restricted access to transplantation for HIV-infected kidney recipients. However, HCV-infected recipients, owing to the historic limitations of HCV therapy in patients with renal disease, are commonly viremic at transplant and have universal access. To compare the effect of HIV, HCV, and HIV/HCV coinfection on kidney transplant patient a...

Sofosbuvir and daclatasvir

After entering hepatocytes, the viral genome of the hepatitis C virus (HCV) is translated into a single polypeptide. This polypeptide is subsequently cleaved into viral proteins, including non-structural (NS) proteins NS3, NS4A, NS5B and NS5B RNA dependent RNA polymerase (Figure 1) [3, 4]. These viral proteins are essential for viral replication and assembly making them significant targets for ...

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

BACKGROUND All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3. METHODS In this open-label study, we initially randomly assigned 44 previously untreated pa...

Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection

AIM To assess the efficacy and safety of sofosbuvir and daclatasvir regimens for kidney transplantation (KT) patients with hepatitis C virus (HCV) infection. METHODS This study enrolled a prospective cohort of consecutive Chinese KT patients with HCV infection. They were given sofosbuvir combined with daclatasvir, with or without ribavirin. They were monitored regularly during and after the t...